Skip to content
Concept demo

A fictional brand, designed and built by Get Ranked On Top. Not a real company.

Skip to content
Vol. VII · Annual Monograph 2026Cambridge, MassachusettsClinical-stage

Rewriting the rarest diseases.

Sorrel Therapeutics develops precision genetic medicines for conditions so uncommon that most physicians will never meet a single patient. We believe each of them deserves the full weight of modern science.

Abstract double helix: a crimson strand and a graphite strand joined by fine rungs.
Fig. 1The instruction and its counterpart. An abstraction of the molecule our work begins and ends with.
Disorders mapped in Atlas
1,140
Programmes
6
In clinical study
3
Colleagues
214
Platform

Three disciplines, held to one standard of evidence.

A rare disease is rarely simple. Our platform is organised around the three questions every programme must answer before it earns a place in the portfolio: is the cause certain, can a medicine reach it, and will we be able to see whether it helped.

Each pillar is shared across programmes, so what we learn in one disease shortens the road for the next.

Finding the single letter that matters

Atlas

Fig. 2Variant field. Highlighted points mark candidates that clear our evidence threshold.

Most rare diseases begin with one small error in a vast text. Atlas is our computational map of those errors — built from consented, de-identified natural-history data and our own functional genomics — so that we choose targets where the biology is unambiguous before we commit a single year to them.

Arriving where the disease lives

Vessel

Fig. 3Schematic carrier. Concentric shells denote the layered design, not physical scale.

A correct medicine is only useful if it reaches the right cells. Vessel is a family of proprietary delivery systems designed for tissue selectivity — liver, muscle and the central nervous system — so that each programme starts with a credible route to the organ that needs it.

Measuring what patients notice

Ledger

Fig. 4Illustrative trajectory. Solid line: programme signal; dashed: natural history.

Endpoints in small populations must be chosen with unusual care. Ledger pairs digital measures with patient-reported outcomes developed alongside advocacy groups, so that what we measure in a trial reflects what a family would recognise as change at home.

Pipeline

Six programmes. Each one a promise to a community.

Select a programme to see where it stands. Stages reflect our own assessment as of October 2026; all programmes are investigational and none is approved for use.

  • Our most advanced programme, designed to restore a missing liver enzyme. Phase II enrolment is under way across four sites.

    Next milestone: Phase II interim readout, H2 2027

    Stage 4 of 5Investigational · not approved
  • A muscle-directed programme developed with our family advisory council, whose outcome measures were co-designed with caregivers.

    Next milestone: Phase I completion, 2027

    Stage 3 of 5Investigational · not approved
  • The first programme to use our central-nervous-system delivery approach in the clinic.

    Next milestone: first cohort complete, 2027

    Stage 3 of 5Investigational · not approved
  • Preclinical package in preparation ahead of a regulatory submission to begin clinical study.

    Next milestone: IND submission, 2027

    Stage 2 of 5Investigational · not approved
  • Selected by Atlas for the strength of its genetic evidence and the clarity of its natural history.

    Next milestone: candidate nomination, 2026

    Stage 2 of 5Investigational · not approved
  • A portfolio of early research targets across liver and muscle, prioritised quarterly against our evidence framework.

    Next milestone: two nominations, 2027

    Stage 1 of 5Investigational · not approved
Publications

We publish what we learn.

Including the negative results. Small populations cannot afford duplicated effort, so our natural-history data and methods frameworks are shared with the field through peer-reviewed literature.

  1. 2026

    A functional atlas of loss-of-function variants across 212 ultra-rare metabolic disorders.

    Okafor N, Lindqvist H, Varga E, et al. Annals of Translational Genomics. 14(3): 201–219.

  2. 2025

    Tissue-selective delivery as a design constraint, not an afterthought: a framework for rare-disease portfolios.

    Marchetti C, Okafor N, Duval S. Review of Genetic Medicine. 9: e1142.

  3. 2025

    Co-designing patient-reported outcomes with families living with neuromuscular rare disease.

    Haddad R, Thorne J, Brennan-Wu L, et al. Journal of Patient-Centred Research. 22(1): 44–58.

  4. 2024

    Natural-history registries in populations under one thousand: lessons from a decade of observation.

    Lindqvist H, Marchetti C. Orphan Disease Quarterly. 31(4): 377–390.

  5. 2023

    Prioritising targets when every patient counts: an evidence-weighting model for rare-disease discovery.

    Okafor N, Varga E. Computational Biology Letters. 7: 88–97.

Patients & Families

You are not a data point. You are the reason.

Many of the families we work with spent years searching for a name for what was happening to them. When they find us, they deserve honesty, patience and someone who picks up the phone.

Our Patient Partnerships team is made up of parents, siblings and nurses. They will never promise more than the science can support — but they will always tell you what we know, and what we are still learning.

They asked what a good day looked like for our daughter, and then they built their study around it.
— Parent and advisory council member, 2025

Talk to a person

Weekdays, 8am–6pm Eastern. A member of our team will answer, not a menu.

Family advisory council

Twenty-two caregivers who review our study designs and hold us to the plain-language standard.

Travel & support

For families taking part in a study, we arrange and cover travel so geography never decides who can join.

Leadership

Scientists, clinicians and a parent who would not wait.

Sorrel was founded by people who had spent their careers watching promising rare-disease work stall for want of commercial interest. We built the company so that it would not.

Dr. Nkem Okafor

Co-founder & Chief Executive Officer

Previously led genetic medicine research at a global biopharmaceutical group. Trained as a paediatric geneticist.

Dr. Henrik Lindqvist

Co-founder & Chief Scientific Officer

Twenty years in functional genomics; architect of the Atlas platform and author of more than ninety papers.

Dr. Chiara Marchetti

Chief Medical Officer

Has guided eleven rare-disease programmes into the clinic and four through registrational studies.

Rania Haddad

Head of Patient Partnerships

Founded a family advocacy network after her son’s diagnosis; joined Sorrel as its twelfth employee.

James Thorne

Chief Financial Officer

Two decades in life-sciences finance, including three public listings and a long-dated royalty financing.

Dr. Eszter Varga

SVP, Computational Biology

Leads the forty-person data science group behind Atlas and Ledger.

Investors

Patient capital for patient science.

We are backed by long-horizon investors who understand that rare-disease medicine is built in years, not quarters. Our capital plan funds every current programme through its next major readout.

Demo form · nothing is sent

  1. 2019

    Founded in Cambridge, MA with seed funding from two founding investors.

  2. 2021

    Series A of $118M. Atlas platform reaches 200 characterised disorders.

  3. 2023

    First programme, SRL-101, receives clearance to begin clinical study.

  4. 2024

    Series B of $240M. Strategic research collaboration announced.

  5. 2025

    SRL-101 advances to Phase II. Orphan designations granted for two programmes.

  6. 2026

    Six programmes in the portfolio; three in the clinic.

$412M
raised to date
6
programmes in the portfolio
3
programmes in clinical study
2031
cash runway, on current plan
Questions

Asked, and answered plainly.

What does “clinical-stage” mean for Sorrel?

It means at least one of our investigational medicines is being studied in people under regulatory oversight. None of our programmes is approved, and none should be described as a treatment yet. We publish what we learn, including results that disappoint us.

Why focus on diseases this rare?

Because rarity is not the same as unimportance. Taken together, rare conditions touch an extraordinary number of families, and most of those conditions still have no approved therapy. Genetic medicine lets us address many of them with a shared set of tools, which changes the economics of caring about small populations.

How can my family learn whether a study is right for us?

Start with your own physician, who knows your history. Our Patient Partnerships team can explain, in plain language, which studies are active and how eligibility generally works. We cannot give medical advice, and we never ask families to pay to take part.

Do you offer access to investigational medicines outside of trials?

We maintain a published expanded-access policy and review every physician request individually and promptly. Requests must come from a treating physician; we respond to each one in writing.

Is Sorrel publicly traded?

Sorrel is a privately held company. Investor materials on this page are summaries; detailed information is shared with prospective investors under the appropriate agreements.

Sorrel Therapeutics

One Sorrel Yard, Cambridge, Massachusetts. Precision genetic medicines for rare disease.